Paediatrics Search
Paediatrics Paediatrics
diabetes%20mellitus%20(pediatric)
DIABETES MELLITUS (PEDIATRIC)
Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
It can occur at any age and the earlier the onset, the more serious is the long-term damage, dysfunction and failure of various organs due to the chronic hyperglycemia with diabetes mellitus patients having <10 year in life span compared to non-DM patients.
Type 1 DM patients have complete insulin deficiency due to beta-cell destruction. It may be immune-mediated or idiopathic. More commonly occurs in children 7-15 year of age, but may occur at any age.
Type 2 DM patients have insulin resistance and relative insulin deficiency.
Neonatal DM is hyperglycemia that occurs in the first 6 months of life.

Diabetes Mellitus (Pediatric) Drug Information

Drug Information

Indication: NIDDM (type 2) in adults when dietary measures, physical exercise & wt loss alone are not sufficient to co...

Indication: Adults, adolescents & childn ≥6 yr w/ DM.

Indication: Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to die...

Indication: Once daily SC administration for DM in adults, adolescents & childn ≥2 yr.

Indication: DM in adults, adolescents & childn ≥2 yr.

Indication: DM requiring insulin.

Indication: DM in adults, adolescents & childn ≥2 yr.

Indication: Monotherapy or in combination w/ other oral antidiabetics or insulin in type 2 DM inadequately controlled by d...

Indication: Adults, adolescents & childn ≥2 yr w/ DM where treatment w/ insulin is required.

Indication: NIDDM when hyperglycemia cannot be controlled by diet management, exercise or wt reduction. Monotherapy or adj...

1  /  7
1  /  7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rheuma drug shows disease-modifying potential for T1D
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).